Literatur
-
1 Burg G, Dummer R. Strategies for Immunointervention in Dermatology. Springer, Berlin 1997
-
2
Cascinelli N, Bufalino R, Morabito A, Mackie R.
Results of adjuvant interferon study in WHO melanoma programme [letter].
Lancet.
1994;
343
913-914
-
3
Dummer R, Gore M, Hancock B. et al .
A multicenter phase II clinical trial using dacarbazine and continuous infusion of interleukin-2 in metastatic melanoma: Clinical data and immunomonitoring.
Cancer.
1995;
75
1038-1044
-
4
Dummer R, Hauschild A, Henseler T, Burg G.
Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma.
Lancet.
1998;
352
908-909
-
5
Dummer R, Nestle F O, Burg G.
Therapie des kutanem Melanoms.
Ther Umschau.
1998;
55
509-514
-
6
Dummer R, Welters H, Keilholz U, Tilgen W, Burg G.
Interleukin 2: immunologischer Hintergrund und Anwendung in der Tumortherapie.
Hautarzt.
1990;
41
53-55
-
7 Garbe C, Dummer R, Kaufmann R, Tilgen W. Dermatologische Onkologie. Springer, Berlin 1998
-
8
Grob J J, Dreno B, delaSalmoniere P. et al .
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases.
Lancet.
1998;
351
1905-1910
-
9
Hauschild A, Dummer R, Garbe C. et al .
Adjuvante Interferon-alpha Therapie beim Melanom. Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie.
Hautarzt.
1998;
49
167-169
-
10
Jäger E, Ringhoffer M, Dienes H P. et al .
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo.
Int J Cancer.
1996;
67
54-62
-
11
Keilholz U, Conradt C, Legha S S. et al .
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
J Clin Oncol.
1998;
16
2921-2929
-
12
Keilholz U, Goey S H, Punt C J. et al .
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
J Clin Oncol.
1997;
15
2579-2588
-
13
Kirkwood J M, Strawderman M H, Ernstoff M S, Smith T J, Borden E C, Blum R H.
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
J Clin Oncol.
1996;
14
7-17
-
14
Kündig T M, Bachmann M F, DiPaolo C. et al .
Fibroblasts as efficient antigen-presenting cells in lymphoid organs.
Science.
1995;
268
1343-1347
-
15
Legha S S, Ring S, Eton O. et al .
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
J Clin Oncol.
1998;
16
1752-1759
-
16
Livingston P.
Ganglioside vaccines with emphasis on GM2.
Semin Oncol.
1998;
25
636-645
-
17
Nestle F O, Burg G, Dummer R.
New perspectives on immunobiology and immunotherapy of melanoma.
Immunol today.
1999;
20
5-7
-
18
Nestle F O, Alijagic S, Gilliet M. et al .
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Nat Med.
1998;
4
328-332
-
19
Pehamberger H, Soyer H P, Steiner A. et al .
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.
J Clin Oncol.
1998;
16
1425-1429
-
20
Zinkernagel R M, Ehl S, Aichele P, Oehen S, Kuendig T, Hengartner H.
Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity.
Immunol Rev.
1997;
156
199-209
Korrespondenz
PD Dr. med. Reinhard Dummer
Dermatologische Klinik, Universitätsspital Zürich
Gloriastrasse 31
CH-8091 Zürich
Telefon: 0041/1/255 25 07
Fax: 0041/1/255 89 88
eMail: dummer@derm.unizh.ch
